Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag The FDA approved a higher-dose Wegovy (7.2 mg) for obese adults who need more weight loss, showing 19% average weight reduction in trials.

flag The FDA has approved a higher-dose version of Wegovy (7.2 mg), now available in April, for adults with obesity who’ve tolerated the 2.4 mg dose and need further weight loss. flag Clinical trials showed the higher dose led to an average 19% body weight loss over 17 months, compared to 16% on the lower dose, with 31% achieving at least 25% weight loss. flag The drug is used with diet and exercise, and side effects including nausea, vomiting, constipation, and a burning skin sensation occurred more frequently. flag Serious adverse events were reported in nearly 7% of users. flag European regulators had already approved the higher dose in February. flag Pricing details are pending.

82 Articles